Cabaletta Bio, Inc. (NASDAQ:CABA – Get Free Report) has received an average rating of “Buy” from the nine analysts that are presently covering the firm, Marketbeat.com reports. One research analyst ...

Cabaletta Bio Inc (CABA) stock saw a decline, ending the day at $2.36 which represents a decrease of $-0.02 or -0.84% from the prior close of $2.38. The stock opened at $2.4 and touched a low of $2.25 ...

The Philadelphia Phillies acquired left-handed starter Jesus Luzardo from the Miami Marlins on Sunday. The team also will ...

Fintel reports that on December 19, 2024, Wells Fargo downgraded their outlook for Cabaletta Bio (NasdaqGS:CABA) from ...

The Philadelphia Phillies and Miami Marlins struck a four-player trade on Sunday centered around left-handed pitcher Jesús ...

The Prospects Live crew breaks down the tools of their 2nd-ranked player in the Philadelphia Phillies farm system, infield ...

Philadelphia upgrades its starting rotation mix with southpaw Jesús Luzardo. How does the move impact top prospect Andrew ...

The Philadelphia Phillies have reportedly added to their already strong rotation. Per The Athletic's Matt Gelb, the Phillies traded 19-year-old ...

The Marlins acquired Caba and Emaarion Boyd from the Phillies on Sunday in exchange for left-hander Jesus Luzardo, Mark Feinsand of MLB.com reports.

Evercore ISI lowered shares of Cabaletta Bio (NASDAQ:CABA – Free Report) from an outperform rating to an inline rating in a research note published on Friday morning, MarketBeat.com reports. They ...

The Philadelphia Phillies have bolstered their rotation via trade, acquiring a left-handed starter from a division rival, ...

PHILADELPHIA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell ...